Results were announced from a phase 3 trial evaluating solriamfetol for major depressive disorder with/without severe excessive daytime sleepiness.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report)‘s stock had its “buy” rating reissued by analysts at Needham & Company ...

Axsome Therapeutics said it's dopamine and norepinephrine reuptake inhibitor solriamfetol (Sunosi), approved for excessive daytime sleepiness, failed to reduce symptoms of major depressive disorder in ...

ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.

After Axsome Therapeutics (AXSM) yesterday reported negative results from its Phase 3 major depressive disorder trial evaluating Sunosi as a ...

Among patients with obstructive sleep apnea and excessive daytime sleepiness-related cognitive impairment, 2-week solriamfetol led to cognitive function improvement on three tests/scales, according to ...

KLP Kapitalforvaltning AS acquired a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities ...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in patients with attention-deficit/hyperactivity ...

Axsome Therapeutics posted mixed results for its experimental depression treatment on Tuesday, leading Axsome stock to dive.

Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes ...

Axsome Therapeutics said Tuesday that a Phase 3 trial for its narcolepsy drug Sunosi failed to meet its primary goal in major ...

Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients ...